Status:
COMPLETED
Faslodex Advanced Breast Cancer Local Chinese Study
Lead Sponsor:
AstraZeneca
Conditions:
Advanced Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
This study will evaluate the efficacy and safety of Faslodex as secondary-line treatment compared with Arimidex in oestrogen receptor positive postmenopausal advanced breast cancer.
Eligibility Criteria
Inclusion
- Postmenopausal advanced breast cancer with oestrogen receptor positive
- Progression under first-line anti-oestrogen therapy.
Exclusion
- Life-threatening metastasis; contraindication to anastrozole
- \>2 regimens of hormonotherapy for advanced breast cancer
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
234 Patients enrolled
Trial Details
Trial ID
NCT00327769
Start Date
November 1 2005
End Date
September 1 2007
Last Update
January 25 2011
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Beijing, China
2
Research Site
Dalian, China
3
Research Site
Fuzhou, China
4
Research Site
Guangzhou, China